Targets › FGFR
5 programs from 5 companies in 5 trials: 4 Phase 2, 1 Phase 1; Oncology, Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: the race on FGFR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jiangxi Provincial Cancer Hospital | Anlotinib hydrochloride Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, RET, KIT) | VEGFR, FGFR, RET, KIT | Phase 2 | Esophageal Squamous Cell Carcinoma | Nov 2026 |
| University of Utah | XL092 (Zanzalintinib) Multi-target kinase inhibitor targeting FGFR, VEGFR, and KIT | FGFR, VEGFR, KIT | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Anlotinib hydrochloride Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR inhibitor) | VEGFR, FGFR, PDGFR | Phase 2 | Sarcoma,Soft Tissue | Dec 2027 |
| Eye & ENT Hospital of Fudan University | Anlotinib Hydrochloride Multi-target tyrosine kinase inhibitor | VEGFR, FGFR, RET, KIT | Phase 2 | Adenoid Cystic Carcinoma | Jun 2028 |
| Peking University First Hospital | Donor NK cells injection Non-genetically modified natural killer cells therapy | FGFR | Phase 1 | Acute Myeloid Leukemia (AML) | Dec 2026 |
Acute Myeloid Leukemia (AML) (1) Esophageal Squamous Cell Carcinoma (1) Metastatic Castration-resistant Prostate Cancer (1) Adenoid Cystic Carcinoma (1) Sarcoma,Soft Tissue (1)
small molecule (4), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.